Strategy doesn't fail at the analysis. It fails at the decision.
Brand Strategy
Built for pharma leaders preparing to launch or protect market share
Commercial Operations
Built for teams making high-stakes decisions on incomplete information
Competitive Intelligence
Ensure decisions hold up through personnel changes & competitive shifts
Not another analytics layer, but the decision infrastructure underneath your commercial operation. This is what it looks like when strategy holds and execution actually follows.
Pharma decisions get reviewed by medical, legal, and regulatory before they go anywhere. They get challenged in brand planning. They get revisited when the market moves. Most AI tools aren't built for that environment. They produce outputs that look right until someone asks a hard question. Axonal is built for the hard question.
Every output shows its work. No black-box conclusions, no recommendations that can't be traced. When a decision gets challenged in a review meeting, you have the evidence and the logic to defend it.
Citations and sources are embedded into every Decision Object, built in from the start. Your team doesn't have to go back and reconstruct the case. It's already there.
AI structures the decision. Your team makes it. Control stays where accountability lives, with the people who will be asked to defend the outcome. Axonal is designed to sharpen judgment, not replace it.
HIPAA-aligned. SOC 2-aligned. AES-256 encryption at rest, TLS in transit, org-scoped data isolation, and client-controlled retention. Your data stays in your environment. Full stop.
Every decision, every revision, every action triggered downstream is logged. When a regulator, a medical reviewer, or a new CMO asks what was decided and why, the answer is accessible and complete.
One object that drives execution. No gaps between what was decided, why it was decided, and what gets done.
Most commercial decisions exist in three places simultaneously: a slide nobody revisits, an inbox thread nobody can find, and the memory of the person who was in the room. None of those survive a leadership change, a team handoff, or a regulatory review.
A Decision Object changes that. It is a structured, persistent record of a decision that travels with the decision, not behind it.
Decision Object Architecture
Decision Objects govern what should be done and why.
Actions govern how it gets done and by whom.
The connection between them is what closes the gap between strategy and execution permanently, not meeting by meeting.
Decision in Practice
A specialty pharma team preparing for launch faced a field force prioritization decision with no clean answer. Higher-experience prescribers offered predictability but slower acceleration. Earlier adopters offered speed but higher access and education friction. The wrong call would either cap near-term impact or overwhelm a limited field team at the worst possible moment.
Axonal structured the decision across three dimensions: adoption velocity, access friction and educational burden. This forces explicit tradeoffs instead of average assumptions. The output wasn't a recommendation. It was a Decision Object — the chosen direction, the conditions under which it held, the signals that would trigger a course correction, and the rationale the team could defend six months later. Field effort aligned to highest-acceleration segments. Risk was managed before the quarter started, not discovered inside it. This is what a Decision Object does in practice. Not analysis. A decision that has everything a team needs to act on it and return to it.
Specialty Pharma · Field Force Strategy
Should the brand pivot positioning to lead with unmet needs in diagnosed patients or maintain the current mechanism of action (MOA) framework for the upcoming launch?
Adopt positioning focused on unmet patient needs to secure market access
Recommend leading with clinical differentiation based on diagnosed patient metrics rather than MOA. Payer reimbursement thresholds require immediate proof of clinical value, which the current MOA framework fails to deliver without Phase 3 head-to-head data.
Update core launch deck to remove MOA-forward positioning narrative.
Route new unmet-need messaging variants to MLR/PRC compliance review.
Initiate Q3 payer landscape monitoring to track reimbursement shifts.
Specialized agents work inside structured workflows. Every output is explainable, reviewable, and logged.
Finds, filters, and cites the most relevant internal and external evidence.
Synthesizes signals, tests scenarios, and surfaces implications.
Packages outputs into decision and actions that persist and scale.
Axonal deploys through structured engagements built around the decisions that matter most. Each pack delivers a defined set of Decision Objects with the evidence, rationale, and execution guidance to act on them.
For brands preparing to enter the market. Five Decision Objects covering positioning, messaging, competitive response, field prioritization, and market access strategy.
Cost & Delivery
Delivered in four to six weeks starting at $100K
For in-market brands facing competitive pressure or evolving evidence. Five Decision Objects: competitive response, evidence strategy, narrative momentum, market risk, and signal monitoring.
Cost & Delivery
Delivered in four to six weeks from $60K to $100K
For teams facing a specific market event (a competitor readout, a label update, a congress moment) that demands a defensible decision inside 48 hours.
Cost & Delivery
$15K to $30K per event, annual monitoring from $120K to $250K